Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of CACS and the development of promising pharmacologic ...

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

A study describes the generation of a new mouse model that could lead to a better understanding of the cachexia syndrome. A study published in Cell Reports Aug. 6 describes the generation of a new ...

Cancer ravages both body and mind. If you've ever lost loved ones to the disease, you might recognize the physical and emotional changes cancer patients often endure during their final months. They ...

Last year, Alice Golden, a two-time cancer survivor living in Billings, Montana, was diagnosed with stage III anal cancer. During her treatment, she developed cachexia. Handling her loved ones' ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

A multidisciplinary team of researchers has identified Upd3, a cytokine, as an important modulator of tumor growth and host wasting via activation of JAK/STAT signaling. Cancer therapy has shown ...